Skip to main content
Erschienen in: Respiratory Research 1/2006

Open Access 01.12.2006 | Review

Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations

verfasst von: Maria Tsoumakidou, Nikolaos M Siafakas

Erschienen in: Respiratory Research | Ausgabe 1/2006

Abstract

Airway inflammation increases during acute exacerbations of COPD. Extrinsic factors, such as airway infections, increased air pollution, and intrinsic factors, such as increased oxidative stress and altered immunity may contribute to this increase. The evidence for this and the potential mechanisms by which various aetiological agents increase inflammation during COPD exacerbations is reviewed. The pathophysiologic consequences of increased airway inflammation during COPD exacerbations are also discussed. This review aims to establish a cause and effect relationship between etiological factors of increased airway inflammation and COPD exacerbations based on recently published data. Although it can be speculated that reducing inflammation may prevent and/or treat COPD exacerbations, the existing anti-inflammatory treatments are modestly effective.
Hinweise

Competing interests

The author(s) declare that they have no competing interests.

Background

Exacerbations are a cardinal feature of the natural history of moderate and severe Chronic Obstructive Pulmonary Disease (COPD)[1]. Patients with frequent exacerbations have significantly lower quality of life and increased morbidity and mortality rates [14]. Although the effect of COPD exacerbations on lung function has been questioned in the past, recent evidence suggests that exacerbations accelerate long-term decline in lung function, specifically in smokers [57]. The mechanism of this acceleration remains largely unknown.
Treatment decisions for COPD patients are frequently made according to exacerbation rates. In the ATS/ERS guidelines it is stated that patients with frequent exacerbations should be initiated a trial of inhaled steroids[8]. Systemic steroids should be administered during acute COPD exacerbations, both in the inpatient and outpatient setting. These treatment strategies indicate the central role of inflammation in the pathogenesis of exacerbations.
Although evidence for increased inflammation on COPD exacerbations has been reviewed previously, there has been little focus on why inflammation increases and which the consequences of this increase are[9, 10]. Investigating further these important questions may help establish a cause and effect relationship between inflammation and COPD exacerbations. The primary aim of this review is to summarize emerging explanations for why inflammation is increased during COPD exacerbations. For practical purposes an attempt is made to categorize aetiological factors of increased inflammation into extrinsic or intrinsic, as it can be seen in table 1. A secondary aim is to try to explain how increased inflammation is associated with the pathophysiology of COPD exacerbations.
Table 1
Aetiology of increased airway inflammation during COPD exacerbations
EXTRINSIC FACTORS
INTRINSIC FACTORS
1. Acute airway infections
a. Bacterial
H. Influenzae
S. pneumoniae
M. Cattarhalis
b. Viral
Rhinoviruses
Picornaviruses
RSV
Influenza A, B
Coronaviruses
c. Atypical
C. Pneumonia
2. Air pollution
1. Oxidative stress
2. Altered immunity
Tc1/Tc2 imbalance
3. Increased inflammation on stable state
Bronchiectasis
Bacterial Colonization

Aetiology of increased inflammation on exacerbations

Extrinsic factors

1. Airway infections

1a Bacterial infections
Bacterial infections are generally considered to be the most common causes of COPD exacerbations. It is estimated that more than 40% of all exacerbations are of bacterial origin[9, 11, 12]. Accordingly, antibiotics should be administered in inpatients and outpatients with acute COPD exacerbation and changes in sputum characteristics suggestive of bacterial infection[8].
The most common bacteria connected to COPD exacerbations are non-typable H. Influenzae, S. Pneumoniae, and M. Cattarhalis[9, 11, 12]. The same bacteria often colonize the nasal mucosa and pharynx of healthy individuals, but in smokers and in patients with COPD impaired mucocilliary clearance and innate immunity allow these pathogens to colonize the lower airways[13]. COPD exacerbations may be triggered by the acquisition of a new bacterial species or by an increase in the absolute number of the same bacteria that colonize the airways or by the acquisition of a different strain from the same bacterial species [1416].
Airway bacteria initiate airway inflammation through several interconnecting mechanisms. The surface of bacteria allows the complement system to be activated through the alternative pathway, while specific surface molecules of the bacteria, called Pathogen-Associated Molecular Patterns (PAMPs), bind to pattern recognition receptors on a variety of leukocytes and initiate signalling pathways that lead to the activation of NF-κB and production of proinflammatory cytokines[17]. Once activated, innate immunity can trigger both cell-mediated and antibody-mediated adaptive immune responses. This cascade of events leads to increased blood flow to tissue, increased temperature, redness and swelling which characterize inflammation.
A significant number of studies in stable COPD patients suggest that airway bacterial infections are associated with increased airway inflammation(18–21). Finding a relationship between bacteria and inflammation on stable COPD adds weight to the argument that bacteria may play a causative role in airway inflammation during COPD exacerbations.
Soler et al used protected specimen brush and bronchoalveolar lavage sampling to determine inflammatory cell counts, levels of cytokines concentrations and microbial patterns in stable COPD patients and found that increased neutrophils and tumour necrosis factor-alpha (TNF-alpha) levels may be related to bronchial colonization[18]. Increased TNF-alpha, as well as myeloperoxidase (MPO) and interleukin-8 (IL-8) levels have been specifically related with H. Influenzae infection, as shown by Bresser et al[19]. However, in that study all mediators were measured in frozen sputum and MPO and IL-8 levels were only retrospectively compared to non-infected patients. In fresh sputum samples from COPD patients R. Stockley and his group demonstrated that MPO, neutrophil elastase (NE) activity, IL-8 and LTB4 levels are positively related to sputum bacterial load[20]. Moreover, the type of organism affected sputum MPO levels and NE activity; MPO levels were relatively increased in the presence of Ps. Aeruginosa compared to H. Influenzae and to M. Catarrhalis. There have been also reports for decreased secretory leukocyte protease inhibitor (SLPI) in sputum samples from COPD patients colonised with bacteria[20, 21]. Upper airways inflammation in COPD is also increased when there is bacterial colonization[22]. All these results taken together suggest that bacteria are actively involved in the mechanisms of increased inflammation in stable COPD. It would be logical to assume a similar association for COPD exacerbations.
A large prospective longitudinal study by Sethi et al addressed the hypothesis that patients with bacterial-positive exacerbations show increased inflammation compared to bacterial-negative exacerbations[23]. Among H. Influenzae, H. Parainfluenzae and M. Catarrhalis positive exacerbations, H. Influenzae and M. Catarrhalis demonstrated higher sputum TNF-alpha and NE levels compared to bacterial-negative exacerbations. Moreover, increased NE levels above a certain level could distinguish bacterial from non-bacterial exacerbations with 71% sensitivity and 84% specificity. Others have failed to report any difference in sputum NE levels and other fluid-phase mediators between patients with H. Influenzae exacerbations or bacterial-negative exacerbations[24]. This discrepancy may be due to differences in sputum induction time or in sputum processing or in the assays used for the detection of fluid-phase mediators. Another intriguing hypothesis is that different strains of the same pathogens may induce different levels of inflammation and subjects taking part in different studies might have been infected by different strains of H. Influenzae. It was recently shown that H. Influenzae strains isolated from COPD patients during exacerbation induce more inflammation than strains of the same pathogen isolated from colonizers[16]. The close association between airway infections and increased inflammation during COPD exacerbations has been further confirmed by a report of increased systemic inflammation in infected patients during exacerbation[25].
Consistent with these observations, airway inflammation can be decreased with treatment of the infection. Early evidence came from a relatively small study, which showed that neutrophilic mediators' levels may decrease after treatment of bacterial exacerbations[26]. Gompertz et al confirmed that there are significant decreases in neutrophilic inflammatory mediators after treatment of purulent exacerbations[27]. Most importantly, White et al studied patients with bacterial exacerbations and demonstrated a significant fall in sputum leukotriene B4 (LTB4) levels and an increase in SLPI levels in patients in whom bacteria were eradicated, but not in those in whom bacteria persisted on stable state[24]. Moreover, MPO and LTB4 levels were significantly lower and SLPI levels significantly higher in patients with treated compared to patients with untreated bacterial infections on stable state.
In conclusion, three major findings support the hypothesis that bacterial infections are actively implicated in the mechanisms of increased airway inflammation during COPD exacerbations: 1) bacterial infections increase airway inflammation in colonized stable COPD patients 2) bacterial-positive exacerbations show increased inflammation (particularly of neutrophilic type) compared to bacterial-negative exacerbations and 3) eradication of bacteria after a bacterial exacerbation is accompanied by a significant decrease in airway inflammation. A summary of these findings is presented in table 2.
Table 2
Studies showing an association between bacterial infections and airway inflammation in stable COPD and on exacerbations
Year
Author
Main finding
1999
Soler
Increased NEU, TNF-a in colonized pts
2000
Bresser
Increased TNF-a, MPO, IL-8 in H. Influenzae colonized pts
2000
Hill
Positive relation between MPO, NE, IL8, LTB4 and bacterial load in stable state. Increased MPO and decreased SLPI in Ps. Aeroginosa colonized pts
2000
Sethi
Increased TNFa, NE in H. Influenae and M. Catarrhalis exacerbations
2000
Crooks
Decrease in MPO, IL8, LTB4, after treatment of bacterial exacerbations
2001
Gombertz
Decrease in LTB4 after treatment of purulent exacerbations
2002
Patel
Positive relation between IL8 and bacterial load. Decreased SLPI in colonized pts
2003
White
Decrease in LTB4, increase in SLPI after bacteria eradication on exacerbations
1b Viral infections
Respiratory viruses are important triggers of COPD exacerbations. Initial studies using serology and cell cultures for detecting viral infections suggested that 30% of COPD exacerbations are related to viral infections [2830]. Later studies using the more sensitive method of reverse transcriptase polymerase chain reaction showed that 40%–50% of COPD exacerbations may be secondary to viral infection[31, 32]. Rhinoviruses, picornaviruses, respiratory syncytial virus, influenza A and B and coronaviruses are more frequently detected[31, 32].
Possible mechanisms of viral-induced inflammation have been described. The airway epithelial cell is the principal host cell for most respiratory viruses[33]. Viral replication in the epithelial cell triggers intracellular signalling pathways, including activation of NFκB, which leads to increases in the secretion of multiple cytokines and recruitment of multiple leukocytes to the airways[33]. Antigen presenting cells are of particular importance, because binding of viruses to these cells induces innate and adaptive immune responses and T lymphocyte activation[34].
There is convincing data that viruses induce inflammation in asthma[35]. In animal models of emphysema, latent adenoviral infection amplifies the emphysematous destruction and increases the inflammatory response[36]. In stable COPD latent adenoviral infection has been associated with severe emphysema and increased inflammation[37]. The group of J Wedzicha showed that viral infections might be implicated in the mechanisms of increased airway and possibly systemic inflammation during COPD exacerbations. Plasma IL-6 and fibrinogen levels were higher during viral than non-viral exacerbations, although the difference just failed to reach statistical significance[31]. However, in that study viruses were detected in nasal samples and it has been shown that in COPD patients respiratory viruses are detected more frequently in induced sputum than in nasal lavage[32, 38]. When rhinovirus infection was detected in induced sputum samples a significant correlation was demonstrated between rhinovirus infection and increased sputum IL-6 levels on COPD exacerbations[38].
Further to these observations, two recent studies showed that viral airway infections during COPD exacerbations are related to airway eosinophilia[39, 40]. This new finding may be of particular clinical importance as airway eosinophilia could be used as an indicator of viral infection during an exacerbation. The important role of eosinophils in the pathogenesis of COPD exacerbations is further supported by studies in bronchial biopsies and sputum samples, which show increased eosinophil numbers and eosinophil mediators in COPD patients during exacerbations [4146]. Eosinophils may be actively involved in the pathogenesis of viral-induced COPD exacerbations through the release of destructive enzymes, reactive oxygen species and inflammatory mediators.
1c Atypical bacteria
Atypical pathogens with potential importance in acute exacerbations include M. Pneumoniae, C. Pneumoniae and Legionella spp. Considerable confusion exists in the literature regarding the significance of these potential pathogens in acute exacerbations of COPD[47]. This is partly due to differences in the techniques used to detect the presence of atypical infections. When a fourfold increase in antibody titter or a positive culture or RT-PCR is used, M. Pneumoniae and Legionella are rare and C. Pneumoniae infection may be involved in up to 9% of COPD exacerbations[30, 4850]. Moreover, chronic colonization with C. Pneumoniae may be associated with a higher rate of COPD exacerbations[51]. C. Pneumonia infection can amplify inflammation in the airways of COPD patients by stimulating the production and expression of cytokines, chemokines and adhesion molecules[52]. However, clear evidence showing a direct relationship between increased inflammation and C. Pneumoniae infection during COPD exacerbations is yet lacking[50].

2. Increased air pollution

Epidemiologists have linked ambient particulate air pollution (PM) exposure with exacerbations of pre-existing pulmonary diseases, such as COPD[53]. PM-mediated enhancement of airway inflammation is a central pathogenetic mechanism by which PM exposure leads to exacerbation of inflammatory pulmonary diseases [5456]. It has been suggested that PM exposure induces lung inflammation by an increase in Reactive Oxygen Species[57, 58]. To the best of our knowledge there are no in vivo studies on the effect of PM exposure on airway inflammation in COPD patients. There is also lack of information on airway inflammation during PM exposure induced COPD exacerbations, which may be due to difficulties in defining such exacerbations.

Intrinsic factors

1. Increased oxidative stress

An imbalance between oxidants and antioxidants may be involved in the development of COPD exacerbations. Almost a decade ago Rahman et al showed that plasma Trolox equivalent antioxidant capacity is decreased in patients presenting with acute exacerbation of COPD[59]. Recent reports suggest that 8-isoprostane levels are increased in exhaled breath condensate of COPD patients during exacerbations, while levels of the antioxidant enzyme glutathione(GSH) in bronchoalveolar lavage fluid are decreased[60, 61]. Oxidative stress may be closely associated to increased inflammation during exacerbations[60, 62].
Oxidant stimuli induce cellular expression of inducible nitric oxide synthase and heme-oxygenase-1(HO-1) and increase nitrotyrosine formation. We have shown that there is increased HO-1 expression and nitrotyrosine formation in the airways of COPD patients during severe exacerbations relatively to stable state and that this is accompanied by an increase in indices of neutrophilic inflammation, i.e. neutrophil numbers, MPO and IL-8 levels[62]. Evidence for a close association between oxidative stress, airway neutrophilia and increased IL-8 during severe COPD exacerbations is also supported by Drost et al[60]. A certain limitation in the study by Drost et al is the fact that different patients were examined on exacerbation and on stable state.
Oxidative stress induces the transcription of various inflammatory factors, such as nuclear factor-kappaB (NF-κB) and activator protein-1 (AP-1)[63]. It has been shown that NF-κB DNA binding in sputum inflammatory cells is increased during COPD exacerbations[64]. Other investigators have reported increased nuclear localisation of p65, which is a signal of NF-κB activation, in sputum macrophages during COPD exacerbations[65]. NF-κB is important for transcription of IL-8 gene and oxidative stress may induce or amplify airway neutrophilia by inducing the transcription of IL-8 gene[66]. In support of this hypothesis both we and Drost et al have found increased IL-8 levels and neutrophil numbers associated with increased oxidative stress on severe COPD exacerbations[60, 62].
Activated neutrophils and other inflammatory cells can in turn release reactive oxygen species and increase airway oxidative stress. Because oxidative stress can induce inflammation and vice versa, it is not clear which of the two, oxidative stress or inflammation, is primarily involved in the mechanisms of COPD exacerbations-[the chicken and egg problem].

2. Altered immunity

Alterations in innate and adaptive immunity are implicated in COPD pathogenesis[67]. Evidence favouring participation of the adaptive immune response in COPD includes the several reports of increased numbers of T-lymphocytes, specifically CD8+ve T-cells with a "type 1"profile [6871]. It is still unknown whether these alterations are triggered by cigarette smoking, viral infections, or there is a genetic predisposal. We have recently shown that CD8+ve T lymphocytes may mediate their destructive effects in COPD through increased perforin expression and cytotoxic activity[72]. It would be reasonable to assume that lymphocytes may be implicated in the mechanisms of increased inflammation during COPD exacerbations.
According to our observations changes in lymphocyte subpopulations occur during severe COPD exacerbations[73]. In specific, there is a further increase in CD8+ve T cells and this is rather associated with increased CD8+ve type 2 cells compared to type 1. This finding suggests that Tc1 and Tc2 responses may fluctuate in relation to the different phase (exacerbation versus stable state) of the disease in the same patient. Similar observations have been made in other inflammatory diseases[74]. A relative increase of Tc2 versus Tc1 cells may result in impaired immunity, increased susceptibility to viral infections and increased inflammation [7577].
Although Saetta et al also found increased T cell numbers in endobronchial biopsies from chronic bronchitis patients on mild exacerbations, no difference was detected in CD4 or CD8+ve cell numbers[45]. This discrepancy may be attributed to the fact that we examined sputum samples (not biopsies) from COPD patients (not chronic bronchitis) on severe exacerbation (not mild exacerbation). Moreover, Saetta et al compared different patients on exacerbation and on stable state, which could be a limitation in their study. However, finding increased T cell numbers still adds evidence to the argument that immune responses may be involved in the mechanisms of increased airway inflammation during COPD exacerbations.

3. Increased baseline levels of inflammation

It would be logical to assume that small increases in airway inflammation in patients with already increased baseline levels of inflammation can easily trigger a COPD exacerbation. This presumes the existence of an inflammatory threshold, above which exacerbation occurs. In relation to this hypothesis, Bhowmik et al showed that COPD patients with frequent exacerbations (≥ 3 episodes/year) have increased baseline sputum IL-6 and IL-8 levels[78]. However, it was not examined whether this was related to bacterial colonization, as bacterial colonization can increase airway inflammation and exacerbation rates. The same group also showed faster rises over time in plasma fibrinogen and sputum IL-6 in patients with frequent exacerbations[79].
On the contrary, Gombertz et al did not detect any difference in neutrophilic mediators (including IL-8) between frequent (≥ 3 episodes/year) and infrequent exacerbators[80]. Interestingly, when patients with bronchiectasis were excluded from the analysis, SLPI was found to be lower in COPD patients with frequent exacerbations, which suggests that COPD patients with bronchiectasis may represent a distinct group. Fujimoto et al also report no difference in baseline IL-8 and markers of eosinophilic inflammation between stable and unstable COPD patients[42]. However, results between this and other studies are not comparable due to lower exacerbation rates (mean 1 episode/year) in the unstable COPD group in this study.
In conclusion, data relating baseline airway inflammation to exacerbation frequency are rather controversial. Part of the existing confusion may be due to significant heterogeneity among COPD patients and to the existence of several factors, like bacterial colonization and bronchiectasis that may increase airway inflammation. In particular, COPD patients with bronchiectasis may represent a distinct group characterized by higher rates of bacterial colonization, increased baseline levels of airway inflammation and longer symptom recovery times at exacerbation[81].

Inflammation and pathophysiology of exacerbations

Episodes of COPD exacerbations are characterized by an acute increase in a patient's baseline dyspnoea, cough and/or sputum production[8]. Severe exacerbations are also associated with worsening of pulmonary gas exchange that may lead to hypoxemia with or without hypercapnia[82]. In order to support a role for airway inflammation in COPD exacerbations the mechanisms which are induced by airway inflammation need to be related to the symptoms and pathophysiology of exacerbations.
Increased airway inflammation induces many pathologic changes on the airways. Accumulation of inflammatory cells in the airway mucosa by itself causes airway wall thickening. Inflammatory cells can release potentially harmful mediators, such as proteases and reactive oxygen species[83]. Neutrophil and eosinophil products, like MPO, NE and eosinophilic cationic protein (ECP), have been found increased on exacerbations, and can cause inflammatory damage and increased permeability of the bronchial mucosa, resulting in airway oedema and protein exudation[20, 42, 62, 84]. Inflammatory mediators, like ECP, can also induce bronchoconstriction by increasing achetinocholine release from parasynmpathetic nerves, while others, like NE, increase mucus secretion[85, 86]. Furthermore, mediators of inflammation enhance coughing[87]. Potentially harmful mediators may be released not only by inflammatory cells but also by resident cells. For example, endothelin (ET)-1, which has been found increased on exacerbations, can be released by epithelial cells and stimulates mucus secretion and bronchial hyperesponsiveness[50]. The cascade of the above events leads to significant airway narrowing and increased airway secretions, while the patient suffers from increased cough, sputum, and/or increased dyspnea. The mechanisms of dyspnea are not entirely understood yet, but may be also associated with excessive airway narrowing and dynamic hyperinflation due to increased inflammation [8890].
A brief summary of the pathophysiologic events that may link airway inflammation to the symptoms of COPD exacerbations and to respiratory failure is given in figure 1. Airway narrowing, caused by increased inflammation, leads to expiratory flow limitation and dynamic hyperinflation. Dynamic hyperinflation in turn increases work of respiratory muscles and oxygen consumption, resulting in decreased mixed venous oxygen tension[91]. Airway narrowing also increases ventilation/perfusion inequality, because a greater proportion of blood flow is diverted through lung units with low V'/Q' ratios[91]. The combination of increased ventilation/perfusion inequality and decreased mixed venous oxygen tension significantly worsen gas exchange in patients with severe COPD exacerbations.
Increased airway inflammation would be also expected to increase lung tissue oxygen demand and oxygen consumption. In patients with acute lung injury no relation has been found between pulmonary oxygen consumption and lung inflammation, but there is no relevant data in COPD exacerbations[92].

Anti-inflammatory therapy for exacerbations

Despite the increasing recognition of the importance of airway inflammation in the development of COPD exacerbations, there is still confusion regarding the role of anti-inflammatory strategies in the prevention and treatment of COPD exacerbations[93, 94]. There are studies showing a beneficial effect of inhaled steroids in preventing COPD exacerbations and systemic steroids in treating acute exacerbations, however the overall benefits for COPD patients in these studies are generally modest [9597]. Considering that inflammation in stable COPD is steroid resistant, this should not come as a great surprise[98]. Although the majority of COPD patients respond modestly to steroid therapy, there might be subgroup of patients, those with eosinophilic pattern of inflammation during exacerbations that may benefit the most from steroid administration. There is already evidence that stable patients with high sputum eosinophil counts are steroid responsive, but there is no relevant data on COPD exacerbations[99, 100]. Identifying patients that may benefit from systemic steroid administration during exacerbations is of great importance, due to the serious adverse events frequently observed with this kind of treatment[97].
Other drugs with anti-inflammatory properties, like methylxanthines and mucolytic agents seem not to be effective on COPD exacerbations[8]. B-agonists are mainly administered as bronchodilators, although they may also have an anti-inflammatory role[101]. Novel drugs aimed at inhibiting targets, including NO synthase, phosphodiesterase 4, proteases and various inflammatory mediators have not been tested during exacerbations yet.

Conclusion

It has been long postulated that airway inflammation may be increased during COPD exacerbations and this may be involved in the pathophysiology of exacerbations. There is now sufficient data to support such a hypothesis. Firstly, there are accumulating observations for increased inflammation during COPD exacerbations. Secondly, specific aetiological factors for this increase have been identified. Thirdly, possible mechanisms that may link airway inflammation with the pathophysiology of exacerbations have been unmasked. Despite significant advances in our understanding of the role of inflammation in COPD exacerbations, the existing anti-inflammatory treatments remain modest and there is little overall benefit for the patient. Further research is needed to target therapies to the appropriate patient populations and to develop new therapeutic strategies.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The author(s) declare that they have no competing interests.
Literatur
2.
Zurück zum Zitat Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R: Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004,59(5):387–395.PubMedPubMedCentralCrossRef Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R: Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004,59(5):387–395.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998,157(5 Pt 1):1418–1422.PubMedCrossRef Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998,157(5 Pt 1):1418–1422.PubMedCrossRef
4.
Zurück zum Zitat Burrows B, Earle RH: Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969,280(8):397–404.PubMedCrossRef Burrows B, Earle RH: Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969,280(8):397–404.PubMedCrossRef
5.
Zurück zum Zitat Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002,57(10):847–852.PubMedPubMedCentralCrossRef Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002,57(10):847–852.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Kanner RE, Anthonisen NR, Connett JE: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001,164(3):358–364.PubMedCrossRef Kanner RE, Anthonisen NR, Connett JE: Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001,164(3):358–364.PubMedCrossRef
7.
Zurück zum Zitat Vestbo J, Prescott E, Lange P: Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996,153(5):1530–1535.PubMedCrossRef Vestbo J, Prescott E, Lange P: Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996,153(5):1530–1535.PubMedCrossRef
8.
Zurück zum Zitat Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004,23(6):932–946.PubMedCrossRef Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004,23(6):932–946.PubMedCrossRef
9.
Zurück zum Zitat White AJ, Gompertz S, Stockley RA: Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003,58(1):73–80.PubMedPubMedCentralCrossRef White AJ, Gompertz S, Stockley RA: Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003,58(1):73–80.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Wedzicha JA: Exacerbations: etiology and pathophysiologic mechanisms. Chest 2002,121(5 Suppl):136S-141S.PubMedCrossRef Wedzicha JA: Exacerbations: etiology and pathophysiologic mechanisms. Chest 2002,121(5 Suppl):136S-141S.PubMedCrossRef
11.
Zurück zum Zitat Murphy TF, Sethi S, Niederman MS: The role of bacteria in exacerbations of COPD. A constructive view. Chest 2000,118(1):204–209.PubMedCrossRef Murphy TF, Sethi S, Niederman MS: The role of bacteria in exacerbations of COPD. A constructive view. Chest 2000,118(1):204–209.PubMedCrossRef
12.
Zurück zum Zitat Miravitlles M: Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J Suppl 2002, 36:9s-19s.PubMedCrossRef Miravitlles M: Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J Suppl 2002, 36:9s-19s.PubMedCrossRef
13.
Zurück zum Zitat Sethi S: Bacterial infection and the pathogenesis of COPD. Chest 2000,117(5 Suppl 1):286S-91S.PubMedCrossRef Sethi S: Bacterial infection and the pathogenesis of COPD. Chest 2000,117(5 Suppl 1):286S-91S.PubMedCrossRef
14.
Zurück zum Zitat Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002,347(7):465–471.PubMedCrossRef Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002,347(7):465–471.PubMedCrossRef
15.
Zurück zum Zitat Sethi S, Wrona C, Grant BJ, Murphy TF: Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004,169(4):448–453.PubMedCrossRef Sethi S, Wrona C, Grant BJ, Murphy TF: Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004,169(4):448–453.PubMedCrossRef
16.
Zurück zum Zitat Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC: Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005,172(1):85–91.PubMedPubMedCentralCrossRef Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC: Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005,172(1):85–91.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Kawai T, Akira S: Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005,17(4):338–344.PubMedCrossRef Kawai T, Akira S: Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005,17(4):338–344.PubMedCrossRef
18.
Zurück zum Zitat Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A: Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999,14(5):1015–1022.PubMedCrossRef Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A: Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999,14(5):1015–1022.PubMedCrossRef
19.
Zurück zum Zitat Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R: Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000,162(3 Pt 1):947–952.PubMedCrossRef Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R: Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000,162(3 Pt 1):947–952.PubMedCrossRef
20.
Zurück zum Zitat Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA: Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000,109(4):288–295.PubMedCrossRef Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA: Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000,109(4):288–295.PubMedCrossRef
21.
Zurück zum Zitat Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002,57(9):759–764.PubMedPubMedCentralCrossRef Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002,57(9):759–764.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA: Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005,127(4):1219–1226.PubMed Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA: Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005,127(4):1219–1226.PubMed
23.
Zurück zum Zitat Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF: Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000,118(6):1557–1565.PubMedCrossRef Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF: Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000,118(6):1557–1565.PubMedCrossRef
24.
Zurück zum Zitat White AJ, Gompertz S, Bayley DL, Hill SL, O'Brien C, Unsal I, Stockley RA: Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003,58(8):680–685.PubMedPubMedCentralCrossRef White AJ, Gompertz S, Bayley DL, Hill SL, O'Brien C, Unsal I, Stockley RA: Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003,58(8):680–685.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA: Systemic, Upper and Lower Airway Inflammation at Exacerbation of COPD. Am J Respir Crit Care Med 2005. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA: Systemic, Upper and Lower Airway Inflammation at Exacerbation of COPD. Am J Respir Crit Care Med 2005.
26.
Zurück zum Zitat Crooks SW, Bayley DL, Hill SL, Stockley RA: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000,15(2):274–280.PubMedCrossRef Crooks SW, Bayley DL, Hill SL, Stockley RA: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000,15(2):274–280.PubMedCrossRef
27.
Zurück zum Zitat Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA: Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001,17(6):1112–1119.PubMedCrossRef Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA: Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001,17(6):1112–1119.PubMedCrossRef
28.
Zurück zum Zitat Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH: Role of infection in chronic bronchitis. Am Rev Respir Dis 1976,113(4):465–474.PubMed Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH: Role of infection in chronic bronchitis. Am Rev Respir Dis 1976,113(4):465–474.PubMed
29.
Zurück zum Zitat Buscho RO, Saxtan D, Shultz PS, Finch E, Mufson MA: Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978,137(4):377–383.PubMedCrossRef Buscho RO, Saxtan D, Shultz PS, Finch E, Mufson MA: Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978,137(4):377–383.PubMedCrossRef
30.
Zurück zum Zitat Smith CB, Golden CA, Kanner RE, Renzetti ADJ: Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980,121(2):225–232.PubMed Smith CB, Golden CA, Kanner RE, Renzetti ADJ: Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980,121(2):225–232.PubMed
31.
Zurück zum Zitat Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA: Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001,164(9):1618–1623.PubMedCrossRef Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA: Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001,164(9):1618–1623.PubMedCrossRef
32.
Zurück zum Zitat Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, Bufe A, Schultze-Werninghaus G: Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003,58(1):37–42.PubMedPubMedCentralCrossRef Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, Bufe A, Schultze-Werninghaus G: Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003,58(1):37–42.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Message SD, Johnston SL: Host defense function of the airway epithelium in health and disease: clinical background. J Leukoc Biol 2004,75(1):5–17.PubMedCrossRef Message SD, Johnston SL: Host defense function of the airway epithelium in health and disease: clinical background. J Leukoc Biol 2004,75(1):5–17.PubMedCrossRef
35.
Zurück zum Zitat Gern JE, Busse WW: The role of viral infections in the natural history of asthma. J Allergy Clin Immunol 2000,106(2):201–212.PubMedCrossRef Gern JE, Busse WW: The role of viral infections in the natural history of asthma. J Allergy Clin Immunol 2000,106(2):201–212.PubMedCrossRef
36.
Zurück zum Zitat Meshi B, Vitalis TZ, Ionescu D, Elliott WM, Liu C, Wang XD, Hayashi S, Hogg JC: Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 2002,26(1):52–57.PubMedCrossRef Meshi B, Vitalis TZ, Ionescu D, Elliott WM, Liu C, Wang XD, Hayashi S, Hogg JC: Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 2002,26(1):52–57.PubMedCrossRef
37.
Zurück zum Zitat Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, Rogers RM, Hayashi S, Hogg JC: Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001,164(3):469–473.PubMedCrossRef Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, Rogers RM, Hayashi S, Hogg JC: Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001,164(3):469–473.PubMedCrossRef
38.
Zurück zum Zitat Seemungal TA, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA: Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000,16(4):677–683.PubMedCrossRef Seemungal TA, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA: Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000,16(4):677–683.PubMedCrossRef
39.
Zurück zum Zitat Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL, Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K, Rohde G, Gevaert P, Holtappels G, Fransen L, Borg I, Wiethege A, Arinir U, Tavernier J, Schultze-Werninghaus G, Bachert C, Bocchino V, Bertorelli G, Bertrand CP, Ponath PD, Newman W, Franco C, Marruchella A, Merlini S, Del Donno M, Zhuo X, Olivieri D: Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Am J Respir Crit Care Med 2006,25(4):640–646. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL, Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K, Rohde G, Gevaert P, Holtappels G, Fransen L, Borg I, Wiethege A, Arinir U, Tavernier J, Schultze-Werninghaus G, Bachert C, Bocchino V, Bertorelli G, Bertrand CP, Ponath PD, Newman W, Franco C, Marruchella A, Merlini S, Del Donno M, Zhuo X, Olivieri D: Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Am J Respir Crit Care Med 2006,25(4):640–646.
40.
Zurück zum Zitat Rohde G, Gevaert P, Holtappels G, Fransen L, Borg I, Wiethege A, Arinir U, Tavernier J, Schultze-Werninghaus G, Bachert C: Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2004,135(1):54–61.PubMedCrossRef Rohde G, Gevaert P, Holtappels G, Fransen L, Borg I, Wiethege A, Arinir U, Tavernier J, Schultze-Werninghaus G, Bachert C: Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2004,135(1):54–61.PubMedCrossRef
41.
Zurück zum Zitat Bocchino V, Bertorelli G, Bertrand CP, Ponath PD, Newman W, Franco C, Marruchella A, Merlini S, Del Donno M, Zhuo X, Olivieri D: Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002,57(1):17–22.PubMed Bocchino V, Bertorelli G, Bertrand CP, Ponath PD, Newman W, Franco C, Marruchella A, Merlini S, Del Donno M, Zhuo X, Olivieri D: Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002,57(1):17–22.PubMed
42.
Zurück zum Zitat Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K: Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005,25(4):640–646.PubMedCrossRef Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K: Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005,25(4):640–646.PubMedCrossRef
43.
Zurück zum Zitat Hargreave FE, Dolovich J, Pizzichini E, Pizzichini M: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1996,153(5):1726–1727.PubMedCrossRef Hargreave FE, Dolovich J, Pizzichini E, Pizzichini M: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1996,153(5):1726–1727.PubMedCrossRef
44.
Zurück zum Zitat Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp CE, Pieno M, Zanguochi G, Del Prete G, Fabbri LM: Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996,26(7):766–774.PubMedCrossRef Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp CE, Pieno M, Zanguochi G, Del Prete G, Fabbri LM: Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996,26(7):766–774.PubMedCrossRef
45.
Zurück zum Zitat Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994,150(6 Pt 1):1646–1652.PubMedCrossRef Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM: Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994,150(6 Pt 1):1646–1652.PubMedCrossRef
46.
Zurück zum Zitat Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK: Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001,164(1):109–116.PubMedCrossRef Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK: Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001,164(1):109–116.PubMedCrossRef
47.
Zurück zum Zitat Sethi S: New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2004,17(2):113–119.PubMedCrossRef Sethi S: New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2004,17(2):113–119.PubMedCrossRef
48.
Zurück zum Zitat Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, Chiodo F, Fasoli A, Allegra L: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993,6(1):19–22.PubMed Blasi F, Legnani D, Lombardo VM, Negretto GG, Magliano E, Pozzoli R, Chiodo F, Fasoli A, Allegra L: Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993,6(1):19–22.PubMed
49.
Zurück zum Zitat Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR: Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991,144(6):1408–1410.PubMedCrossRef Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR: Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991,144(6):1408–1410.PubMedCrossRef
50.
Zurück zum Zitat Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, Wedzicha JA: Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001,56(1):30–35.PubMedPubMedCentralCrossRef Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, Wedzicha JA: Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001,56(1):30–35.PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, Allegra L: Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002,57(8):672–676.PubMedPubMedCentralCrossRef Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, Allegra L: Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002,57(8):672–676.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Clementsen P, Permin H, Norn S: Chlamydia pneumoniae infection and its role in asthma and chronic obstructive pulmonary disease. J Investig Allergol Clin Immunol 2002,12(2):73–79.PubMed Clementsen P, Permin H, Norn S: Chlamydia pneumoniae infection and its role in asthma and chronic obstructive pulmonary disease. J Investig Allergol Clin Immunol 2002,12(2):73–79.PubMed
53.
Zurück zum Zitat Sunyer J, Saez M, Murillo C, Castellsague J, Martinez F, Anto JM: Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol 1993,137(7):701–705.PubMed Sunyer J, Saez M, Murillo C, Castellsague J, Martinez F, Anto JM: Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol 1993,137(7):701–705.PubMed
54.
Zurück zum Zitat Ohtoshi T, Takizawa H, Okazaki H, Kawasaki S, Takeuchi N, Ohta K, Ito K: Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro. J Allergy Clin Immunol 1998,101(6 Pt 1):778–785.PubMedCrossRef Ohtoshi T, Takizawa H, Okazaki H, Kawasaki S, Takeuchi N, Ohta K, Ito K: Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro. J Allergy Clin Immunol 1998,101(6 Pt 1):778–785.PubMedCrossRef
55.
Zurück zum Zitat Rudell B, Blomberg A, Helleday R, Ledin MC, Lundback B, Stjernberg N, Horstedt P, Sandstrom T: Bronchoalveolar inflammation after exposure to diesel exhaust: comparison between unfiltered and particle trap filtered exhaust. Occup Environ Med 1999,56(8):527–534.PubMedPubMedCentralCrossRef Rudell B, Blomberg A, Helleday R, Ledin MC, Lundback B, Stjernberg N, Horstedt P, Sandstrom T: Bronchoalveolar inflammation after exposure to diesel exhaust: comparison between unfiltered and particle trap filtered exhaust. Occup Environ Med 1999,56(8):527–534.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Seaton A, MacNee W, Donaldson K, Godden D: Particulate air pollution and acute health effects. Lancet 1995,345(8943):176–178.PubMedCrossRef Seaton A, MacNee W, Donaldson K, Godden D: Particulate air pollution and acute health effects. Lancet 1995,345(8943):176–178.PubMedCrossRef
57.
Zurück zum Zitat Tao F, Gonzalez-Flecha B, Kobzik L: Reactive oxygen species in pulmonary inflammation by ambient particulates. Free Radic Biol Med 2003,35(4):327–340.PubMedCrossRef Tao F, Gonzalez-Flecha B, Kobzik L: Reactive oxygen species in pulmonary inflammation by ambient particulates. Free Radic Biol Med 2003,35(4):327–340.PubMedCrossRef
58.
Zurück zum Zitat MacNee W, Donaldson K: Exacerbations of COPD: environmental mechanisms. Chest 2000,117(5 Suppl 2):390S-7S.PubMedCrossRef MacNee W, Donaldson K: Exacerbations of COPD: environmental mechanisms. Chest 2000,117(5 Suppl 2):390S-7S.PubMedCrossRef
59.
Zurück zum Zitat Rahman I, Morrison D, Donaldson K, MacNee W: Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996,154(4 Pt 1):1055–1060.PubMedCrossRef Rahman I, Morrison D, Donaldson K, MacNee W: Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996,154(4 Pt 1):1055–1060.PubMedCrossRef
60.
Zurück zum Zitat Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W: Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005,60(4):293–300.PubMedPubMedCentralCrossRef Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W: Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005,60(4):293–300.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003,58(4):294–298.PubMedPubMedCentralCrossRef Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003,58(4):294–298.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Tsoumakidou M, Tzanakis N, Chrysofakis G, Siafakas NM: Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest 2005,127(6):1911–1918.PubMedCrossRef Tsoumakidou M, Tzanakis N, Chrysofakis G, Siafakas NM: Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest 2005,127(6):1911–1918.PubMedCrossRef
64.
Zurück zum Zitat Drost EM, Ritchie HE, Skwarska E, al : NF-kB activation in airway leucocytes in COPD patients. Eur Respir J 2001, 16:260s. Drost EM, Ritchie HE, Skwarska E, al : NF-kB activation in airway leucocytes in COPD patients. Eur Respir J 2001, 16:260s.
65.
Zurück zum Zitat Caramori G, Romagnoli M, Casolari P, Bellettato C, Casoni G, Boschetto P, Chung KF, Barnes PJ, Adcock IM, Ciaccia A, Fabbri LM, Papi A: Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 2003,58(4):348–351.PubMedPubMedCentralCrossRef Caramori G, Romagnoli M, Casolari P, Bellettato C, Casoni G, Boschetto P, Chung KF, Barnes PJ, Adcock IM, Ciaccia A, Fabbri LM, Papi A: Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 2003,58(4):348–351.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Roebuck KA: Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med 1999,4(3):223–230.PubMed Roebuck KA: Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med 1999,4(3):223–230.PubMed
67.
Zurück zum Zitat Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004,364(9435):709–721.PubMedCrossRef Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004,364(9435):709–721.PubMedCrossRef
68.
Zurück zum Zitat Tsoumakidou M, Tzanakis N, Kyriakou D, Chrysofakis G, Siafakas NM: Inflammatory cell profiles and T-lymphocyte subsets in chronic obstructive pulmonary disease and severe persistent asthma. Clin Exp Allergy 2004,34(2):234–240.PubMedCrossRef Tsoumakidou M, Tzanakis N, Kyriakou D, Chrysofakis G, Siafakas NM: Inflammatory cell profiles and T-lymphocyte subsets in chronic obstructive pulmonary disease and severe persistent asthma. Clin Exp Allergy 2004,34(2):234–240.PubMedCrossRef
69.
Zurück zum Zitat Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, Bellettato CM, Papi A, Corbetta L, Zuin R, Sinigaglia F, Fabbri LM: Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002,165(10):1404–1409.PubMedCrossRef Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, Bellettato CM, Papi A, Corbetta L, Zuin R, Sinigaglia F, Fabbri LM: Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002,165(10):1404–1409.PubMedCrossRef
70.
Zurück zum Zitat O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997,155(3):852–857.PubMedCrossRef O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997,155(3):852–857.PubMedCrossRef
71.
Zurück zum Zitat Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, Kheradmand F: An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004,1(1):e8.PubMedPubMedCentralCrossRef Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, Kheradmand F: An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004,1(1):e8.PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Chrysofakis G, Tzanakis N, Kyriakoy D, Tsoumakidou M, Tsiligianni I, Klimathianaki M, Siafakas NM: Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest 2004,125(1):71–76.PubMedCrossRef Chrysofakis G, Tzanakis N, Kyriakoy D, Tsoumakidou M, Tsiligianni I, Klimathianaki M, Siafakas NM: Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest 2004,125(1):71–76.PubMedCrossRef
73.
Zurück zum Zitat Tsoumakidou M, Tzanakis N, Chrysofakis G, Kyriakou D, Siafakas NM: Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005,99(5):572–579.PubMedCrossRef Tsoumakidou M, Tzanakis N, Chrysofakis G, Kyriakou D, Siafakas NM: Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005,99(5):572–579.PubMedCrossRef
74.
Zurück zum Zitat Prezzi C, Casciaro MA, Francavilla V, Schiaffella E, Finocchi L, Chircu LV, Bruno G, Sette A, Abrignani S, Barnaba V: Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 2001,31(3):894–906.PubMedCrossRef Prezzi C, Casciaro MA, Francavilla V, Schiaffella E, Finocchi L, Chircu LV, Bruno G, Sette A, Abrignani S, Barnaba V: Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 2001,31(3):894–906.PubMedCrossRef
75.
Zurück zum Zitat Wirth S, van den Broek M, Frossard CP, Hugin AW, Leblond I, Pircher H, Hauser C: CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection. Cell Immunol 2000,202(1):13–22.PubMedCrossRef Wirth S, van den Broek M, Frossard CP, Hugin AW, Leblond I, Pircher H, Hauser C: CD8(+) T cells secreting type 2 lymphokines are defective in protection against viral infection. Cell Immunol 2000,202(1):13–22.PubMedCrossRef
76.
Zurück zum Zitat Kemeny DM, Noble A, Holmes BJ, Diaz-Sanchez D: Immune regulation: a new role for the CD8+ T cell. Immunol Today 1994,15(3):107–110.PubMedCrossRef Kemeny DM, Noble A, Holmes BJ, Diaz-Sanchez D: Immune regulation: a new role for the CD8+ T cell. Immunol Today 1994,15(3):107–110.PubMedCrossRef
77.
Zurück zum Zitat Seder RA, Le Gros GG: The functional role of CD8+ T helper type 2 cells. J Exp Med 1995,181(1):5–7.PubMedCrossRef Seder RA, Le Gros GG: The functional role of CD8+ T helper type 2 cells. J Exp Med 1995,181(1):5–7.PubMedCrossRef
78.
Zurück zum Zitat Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000,55(2):114–120.PubMedPubMedCentralCrossRef Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000,55(2):114–120.PubMedPubMedCentralCrossRef
79.
Zurück zum Zitat Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005,128(4):1995–2004.PubMedCrossRef Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005,128(4):1995–2004.PubMedCrossRef
80.
Zurück zum Zitat Gompertz S, Bayley DL, Hill SL, Stockley RA: Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001,56(1):36–41.PubMedPubMedCentralCrossRef Gompertz S, Bayley DL, Hill SL, Stockley RA: Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001,56(1):36–41.PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA: Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004,170(4):400–407.PubMedCrossRef Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA: Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004,170(4):400–407.PubMedCrossRef
82.
Zurück zum Zitat Calverley PM: Respiratory failure in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003, 47:26s-30s.PubMedCrossRef Calverley PM: Respiratory failure in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003, 47:26s-30s.PubMedCrossRef
83.
Zurück zum Zitat Barnes PJ: Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004,56(4):515–548.PubMedCrossRef Barnes PJ: Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004,56(4):515–548.PubMedCrossRef
84.
Zurück zum Zitat Gompertz S, Stockley RA: Inflammation--role of the neutrophil and the eosinophil. Semin Respir Infect 2000,15(1):14–23.PubMedCrossRef Gompertz S, Stockley RA: Inflammation--role of the neutrophil and the eosinophil. Semin Respir Infect 2000,15(1):14–23.PubMedCrossRef
85.
Zurück zum Zitat Jeffery P, Zhu J: Mucin-producing elements and inflammatory cells. Novartis Found Symp 2002, 248:51–68; discussion 68–75, 277–82.PubMedCrossRef Jeffery P, Zhu J: Mucin-producing elements and inflammatory cells. Novartis Found Symp 2002, 248:51–68; discussion 68–75, 277–82.PubMedCrossRef
86.
Zurück zum Zitat Fryer AD, Adamko DJ, Yost BL, Jacoby DB: Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci 1999,64(6–7):449–455.PubMedCrossRef Fryer AD, Adamko DJ, Yost BL, Jacoby DB: Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci 1999,64(6–7):449–455.PubMedCrossRef
88.
Zurück zum Zitat Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE: Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005,26(3):420–428.PubMedCrossRef Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE: Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005,26(3):420–428.PubMedCrossRef
89.
Zurück zum Zitat Stevenson NJ, Walker PP, Costello RW, Calverley PM: Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005. Stevenson NJ, Walker PP, Costello RW, Calverley PM: Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005.
90.
Zurück zum Zitat Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic SocietyAm J Respir Crit Care Med 1999,159(1):321–340. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic SocietyAm J Respir Crit Care Med 1999,159(1):321–340.
91.
Zurück zum Zitat Barbera JA, Roca J, Ferrer A, Felez MA, Diaz O, Roger N, Rodriguez-Roisin R: Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997,10(6):1285–1291.PubMedCrossRef Barbera JA, Roca J, Ferrer A, Felez MA, Diaz O, Roger N, Rodriguez-Roisin R: Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997,10(6):1285–1291.PubMedCrossRef
92.
Zurück zum Zitat Jolliet P, Thorens JB, Nicod L, Pichard C, Kyle U, Chevrolet JC: Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury. Intensive Care Med 1996,22(4):277–285.PubMedCrossRef Jolliet P, Thorens JB, Nicod L, Pichard C, Kyle U, Chevrolet JC: Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury. Intensive Care Med 1996,22(4):277–285.PubMedCrossRef
93.
Zurück zum Zitat Calverley PM: The role of corticosteroids in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005,26(2):235–245.PubMedCrossRef Calverley PM: The role of corticosteroids in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005,26(2):235–245.PubMedCrossRef
94.
Zurück zum Zitat Wedzicha JA: Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease. Thorax 2000, 55 Suppl 1:S23–7.PubMedCrossRef Wedzicha JA: Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease. Thorax 2000, 55 Suppl 1:S23–7.PubMedCrossRef
95.
Zurück zum Zitat Davies L, Angus RM, Calverley PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999,354(9177):456–460.PubMedCrossRef Davies L, Angus RM, Calverley PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999,354(9177):456–460.PubMedCrossRef
96.
Zurück zum Zitat Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999,340(25):1941–1947.PubMedCrossRef Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999,340(25):1941–1947.PubMedCrossRef
97.
Zurück zum Zitat Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, CD001288. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, CD001288.
98.
Zurück zum Zitat Barnes PJ: Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004,1(3):264–268.PubMedCrossRef Barnes PJ: Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004,1(3):264–268.PubMedCrossRef
99.
Zurück zum Zitat Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID: Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000,356(9240):1480–1485.PubMedCrossRef Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID: Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000,356(9240):1480–1485.PubMedCrossRef
100.
Zurück zum Zitat Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, Bradding P: Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005,60(3):193–198.PubMedPubMedCentralCrossRef Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, Bradding P: Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005,60(3):193–198.PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat Barnes PJ: Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999,104(2 Pt 2):S10–7.PubMedCrossRef Barnes PJ: Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999,104(2 Pt 2):S10–7.PubMedCrossRef
Metadaten
Titel
Novel insights into the aetiology and pathophysiology of increased airway inflammation during COPD exacerbations
verfasst von
Maria Tsoumakidou
Nikolaos M Siafakas
Publikationsdatum
01.12.2006
Verlag
BioMed Central
Erschienen in
Respiratory Research / Ausgabe 1/2006
Elektronische ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-7-80

Weitere Artikel der Ausgabe 1/2006

Respiratory Research 1/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.